Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis

被引：5

作者：

Norimatsu, Yuta ^{[1
]}

Miyagawa, Takuya ^{[1
]}

Fukui, Yuki ^{[1
]}

Omatsu, Jun ^{[1
]}

Toyama, Satoshi ^{[1
]}

Awaji, Kentaro ^{[1
]}

Ikawa, Tetsuya ^{[1
]}

Watanabe, Yusuke ^{[1
]}

Yoshizaki, Ayumi ^{[1
]}

Sato, Shinichi ^{[1
]}

Asano, Yoshihide ^{[1
]}

机构：

[1] Univ Tokyo, Dept Dermatol, Grad Sch Med, Tokyo, Japan

来源：

JOURNAL OF DERMATOLOGY | 2021年 / 48卷 / 08期

关键词：

coagulation; Raynaud’ s phenomenon; systemic sclerosis; telangiectasia; tissue factor pathway inhibitor;

D O I：

10.1111/1346-8138.15893

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Vasculopathy is a critical step of systemic sclerosis (SSc) development, bridging between autoimmune inflammation and tissue fibrosis. Impaired coagulation system is a part of SSc vasculopathy, but the role of tissue factor pathway inhibitor (TFPI), a critical regulator of the extrinsic coagulation pathway, remained unknown. Therefore, we evaluated the clinical correlation of serum TFPI levels in SSc patients. Serum TFPI levels were comparable between SSc and control participants, but SSc patients with Raynaud's phenomenon and telangiectasia had significantly lower serum TFPI levels than those without. Importantly, there was a significant positive correlation between serum TFPI levels and protein S activity. These results support the critical role of impaired coagulation system in SSc.

引用

页码：1253 / 1256

页数：4

共 15 条

[1] Platelet rich plasma enhances the immunohistochemical expression of platelet derived growth factor and vascular endothelial growth factor in the synovium of the meniscectomized rat models of osteoarthritis [J].

Almasry, Shaima M. ;

Soliman, Hala M. ;

El-Tarhouny, Shereen A. ;

Algaidi, Sami A. ;

Ragab, Ehab M. .

ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER, 2015, 197 :38-49

[2] The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies [J].

Asano, Yoshihide .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) :1-27

[3] ULTRASTRUCTURE AND 3-DIMENSIONAL RECONSTRUCTION OF SEVERAL MACULAR AND PAPULAR TELANGIECTASES [J].

BRAVERMAN, IM ;

KEHYEN, A .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1983, 81 (06) :489-497

[4] Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis [J].

Dahm, A ;

Vlieg, AV ;

Bendz, B ;

Rosendaal, F ;

Bertina, RM ;

Sandset, PM .

BLOOD, 2003, 101 (11) :4387-4392

[5] Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S [J].

Ellery, Paul E. R. ;

Hilden, Ida ;

Sejling, Ken ;

Loftager, Mette ;

Martinez, Nicholas D. ;

Maroney, Susan A. ;

Mast, Alan E. .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2018, 2 (01) :93-104

[6] Protein S as Cofactor for TFPI [J].

Hackeng, Tilman M. ;

Rosing, Jan .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (12) :2015-2020

[7] Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice [J].

Huang, ZF ;

Higuchi, D ;

Lasky, N ;

Broze, GJ .

BLOOD, 1997, 90 (03) :944-951

[8] ACTIVE PROLIFERATION OF TELANGIECTASES IN SKIN OF PATIENTS WITH PROGRESSIVE SYSTEMIC-SCLEROSIS (PSS) [J].

KAZANDJIAN, S ;

BRUNEVAL, P ;

FIESSINGER, JN ;

CAMILLERI, JP ;

HOUSSET, E .

ARCHIVES OF DERMATOLOGICAL RESEARCH, 1986, 279 (01) :8-11

[9] Tissue Factor Pathway Inhibitor Multiple Anticoagulant Activities for a Single Protein [J].

Mast, Alan E. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (01) :9-14

[10] Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina [J].

Nishiyama, K ;

Ogawa, H ;

Yasue, H ;

Soejima, H ;

Misumi, K ;

Kugiyama, K ;

Tsuji, I ;

Kumeda, K .

THROMBOSIS RESEARCH, 1998, 89 (03) :137-146

← 1 2 →